Inventory consisted of the following:


	June 30,		December 31,
(In thousands)	2026		2025
Raw materials	$	18,724	$	16,330
Work-in-process		15,123		17,871
Finished goods		5,121		4,971
Total inventory	$	38,968	$	39,172

As of June 30, 2026 and December 31, 2025, total inventory included net fair value adjustments resulting from the acquisition of La Jolla of approximately $1.4 million and $3.4 million, respectively, which will be amortized and recognized as cost of products sold when sales occur in future periods. The fair value adjustments recorded as part of cost of products sold amounted to $0.9 million and $2.0 million for the three and six months ended June 30, 2026, respectively, and $0.4 million and $0.6 million for the three and six months ended June 30, 2025, respectively.

Other accrued liabilities consisted of the following:


	June 30,		December 31,
(In thousands)	2026		2025
Accrued contract manufacturing expenses	$	9,322	$	8,220
Accrued clinical and research expenses		150		185
Accrued professional services		4,979		5,845
Current portion of lease liabilities		712		418
Royalty obligation payable		4,148		3,690
Current portion of deferred royalty obligations		6,302		8,124
Accrued license fees and royalties		2,102		1,964
Other		898		1,022
Total other accrued liabilities	$	28,613	$	29,468

Other long-term liabilities consisted of the following:


	June 30,		December 31,
(In thousands)	2026		2025
Long-term portion of deferred royalty obligation	$	55,280	$	54,104
Long-term portion of lease liabilities		10,491		10,868
Other		1,505		1,119
Total other long-term liabilities	$	67,276	$	66,091